Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-06-04

Clinical Trial Update: A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver [Phase 2]

View source ↗

Summary

Phase 2 study of IMC-A12 plus sorafenib in hepatocellular carcinoma completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • IMC-A12 (cixutumumab)
  • Sorafenib (Sorafenib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2018-06-04